New drug targets for HIV and hepatitis C virus coinfection

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Tedaldi, Ellen M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN ALPHA INTERFERON; ALPHA GLUCOSIDASE INHIBITOR; ALPHA INTERFERON; ANADYS 245; ANTISENSE OLIGODEOXYNUCLEOTIDE; CILUPREVIR; ENFUVIRTIDE; ENZYME INHIBITOR; GAMMA INTERFERON; HELICASE; HEPATITIS C VACCINE; HISTAMINE; IMMUNOGLOBULIN; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; ISATORIBINE; ISIS 14803; LEVOVIRIN; MERIMEPODIB; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA INTERFERON; PEGINTERFERON; RECOMBINANT INTERFERON; RIBAMIDINE; RIBAVIRIN; RIBOZYME; RNA POLYMERASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STRUCTURAL PROTEIN; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMPLANTABLE PORT SYSTEM; INFLAMMATION; LEUKOCYTE; PATIENT COMPLIANCE; PRENYLATION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA SYNTHESIS; SIDE EFFECT; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; RIBAVIRIN; VIRAL HEPATITIS VACCINES; VIRUS REPLICATION;

EID: 20844452411     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429505     Document Type: Review

References (27)

1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peg Interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
2. Chung RT, Andersen J, Volberding P, et al. Peg Interferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
3. Carrat F, Bani-Sadr F, Pol S, et al. ANRS HC02-RIBAVIC Study Team. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-48.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peg Interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
6. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peg interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38:75-85.
7. Theodore D, Shiffman ML, Sterling RK, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003; 48:140-5.
8. Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
9. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1039-46.
10. Plauth M, Meisel H, Langecker P, et al. Open-label phase II study of omega interferon in previously untreated HCV infected patients. Hepatology 2001; 34:331A.
11. Lin CC, Philips L, Xu C, Yeh LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44:265-75.
12. Rossi S, Wright T, Lin CC, Lau JY, Fang JW. Phase I clinical studies of levovirin-a second generation ribavirin candidate. Hepatology 2001; 34:327A.
13. Glesby MJ, Bassett R, Alston B, et al. Pilot study of low dose daily interleukin-2 plus pegylated-interferon-alfa-2b and ribavirin in patients with HCV/HIV co-infection: ACTG A5088 [abstract 818]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:370.
14. Schlaak JF, Schramm C, Radecke K, zum Buschenfelde KH, Gerken G. Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2002; 29:145-8.
15. Pockros PJ, Patel K, O'Brien C, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003; 37:1368-74.
16. Liang TJ, Thomson M. Molecular biology of hepatitis C virus. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego: Academic Press, 2000: 1-24.
17. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-9.
18. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-14.
19. McHutchinson JG, Patel K. Future therapy of hepatitis C. Hepatology 2002; 36:5245-52.
20. Papatheodoridis GV, Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat 2004; 11:287-96.
21. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100:2014-8.
22. Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother 2003; 52:883-6.
23. Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38:66-74.
24. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-23.
25. Adhhal NH, Freilich B, Levine R, et al. Colchicine versus peg-intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2 [poster 171]. In: Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases (Boston). Alexandria, VA: American Association for the Study of Liver Diseases, 2004.
26. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-83.
27. Lanford RE, Guerra B, Chavez D, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78:1575-81.